Form 8-K - Current report:
SEC Accession No. 0001140361-25-001899
Filing Date
2025-01-24
Accepted
2025-01-24 16:34:53
Documents
15
Period of Report
2025-01-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20042243_8k.htm   iXBRL 8-K 32727
2 EXHIBIT 10.1 ef20042243_ex10-1.htm EX-10.1 148643
3 EXHIBIT 10.2 ef20042243_ex10-2.htm EX-10.2 23842
  Complete submission text file 0001140361-25-001899.txt   383106

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ird-20250117.xsd EX-101.SCH 3976
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20250117_lab.xml EX-101.LAB 21966
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20250117_pre.xml EX-101.PRE 16041
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20042243_8k_htm.xml XML 4216
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 25554628
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)